IMPACT THERAP-B (07630) has been included in the Hang Seng Composite Index constituent stocks.
Yin Pai Pharmaceutical-B (07630) announced that it has been selected by the Hang Seng Index Company and will be included in the Hang Seng Composite Index constituents, effective from September 7, 2026.
IMPACT THERAP-B (07630) announced that it has been selected by Hang Seng Indexes Company Limited and will be included in the Hang Seng Composite Index (Hang Seng Composite Index), effective September 7, 2026.
After being included in the Hang Seng Composite Index, the company's shares are expected to meet the criteria for inclusion in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect trading programs. The Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect are channels for investors in Hong Kong and mainland China to trade and invest in stocks.
The company believes that its inclusion in the Hang Seng Composite Index reflects the recognition of its industry position, operational performance, and overall value by the international capital market. This move is expected to enhance the trading liquidity of its shares, broaden and diversify the shareholder base, and contribute to the company's long-term sustainable growth.
Related Articles
KEEP (03650) released its interim results, achieving revenue of 825 million yuan, a year-on-year increase of 0.4%. The revenue from its own branded sports products business grew by 21.7% year-on-year.
Capital from the south continues to increase its position in YIDU TECH (02158), with the first dividend scheduled to be distributed on September 16.
SIPAI HEALTH (00314) turns profit in mid-term performance: Strategic transformation shows results, and the business insurance service landscape continues to expand.
KEEP (03650) released its interim results, achieving revenue of 825 million yuan, a year-on-year increase of 0.4%. The revenue from its own branded sports products business grew by 21.7% year-on-year.
Capital from the south continues to increase its position in YIDU TECH (02158), with the first dividend scheduled to be distributed on September 16.
SIPAI HEALTH (00314) turns profit in mid-term performance: Strategic transformation shows results, and the business insurance service landscape continues to expand.
RECOMMEND
